Vic Veguilla

Vic Veguilla serves as the Program Point of Contact for the Centers for Disease Control and Prevention, playing a critical role in aligning procurement activities with the agency’s public health mission. He facilitates the acquisition of scientific, diagnostic, and technical services essential to disease surveillance, outbreak response, and laboratory capacity building. His responsibilities include coordinating requirements definition, evaluating vendor capabilities, and ensuring contractual deliverables support CDC’s strategic priorities in infectious disease control and biomedical innovation. Veguilla works closely with program scientists and procurement staff to translate technical needs into solicitation language, ensuring acquisitions reflect the latest public health imperatives and scientific standards. Veguilla maintains consistent, high-impact relationships with leading pharmaceutical and biomedical distributors, including Merck Sharp & Dohme LLC, GlaxoSmithKline LLC, Pfizer Inc., Sanofi Pasteur Inc., and McKesson Specialty Distribution LLC. These partnerships primarily support the procurement of vaccines, diagnostic reagents, and specialized distribution logistics critical to national immunization and emergency response programs. His working pattern reflects a preference for established industry leaders with proven regulatory compliance, manufacturing scalability, and cold-chain logistics expertise, ensuring continuity and reliability in mission-critical supply chains. Veguilla’s procurement portfolio reflects no set-aside preferences, with 100% of acquisitions awarded under full and open competition. This indicates a strategic focus on technical capability and operational readiness over socioeconomic classifications, prioritizing the most qualified vendors regardless of business size or certification status. While small business participation is not formally targeted, his approach ensures equitable access through transparent, merit-based evaluation criteria aligned with federal acquisition regulations. His primary procurement focus lies in NAICS 325413 (in-vitro diagnostic substance manufacturing), 541690 (other scientific and technical consulting services), and 541714 (research and development in biotechnology). These categories reflect deep expertise in procuring advanced diagnostic assays, public health analytics services, and biotech R&D solutions that enhance CDC’s ability to detect, analyze, and respond to emerging health threats in real time.